Johnson & Johnson reported sales of blood thinner Xarelto fell 19% to $549 million in the second quarter of 2019 compared ...
While the Trump administration's drug pricing plans have stalled in recent weeks, several Democratic presidential hopefuls have rolled out their own plans to curb rising pharmaceutical costs, poised ...
Recent news and headlines have been saturated with stories about data security and consumer privacy. In the healthcare industry especially, the heightened privacy focus, new policies from ...
Sickle cell disease is one of the most common genetic blood disorders, but treatment options have been mostly limited to blood transfusions and hydroxyurea, a decades-old myelosuppressive drug. While ...
Kite has significantly expanded in the almost two years since Gilead acquired it for $12 billion, reflective of the opportunity Gilead sees in cell therapy. "Cell therapy oncology is in a ...